Biotech Licensing: IMPACT Therapeutics and Pharmanovia struck an exclusive deal for senaparib, pushing the PARP inhibitor beyond China into the EU, UK, Norway, Iceland, Switzerland and Liechtenstein (plus MENA, Australia and New Zealand), with up to €423.5M in upfront and milestone payments and royalties in the mid-20% range. Cancer Pipeline Detail: Senaparib targets PARP1/2 to exploit DNA-repair weaknesses, aiming at 1L maintenance for advanced ovarian, fallopian tube and primary peritoneal cancers after platinum chemotherapy response. COVID Vaccine Update: Pfizer-BioNTech’s XFG-adapted COVID-19 vaccine won European Commission marketing authorisation for EU states plus Iceland, Liechtenstein and Norway, with manufacturing already started for the upcoming respiratory season. Crypto Regulation: ESMA added 15 crypto-asset service providers to the MiCA register, bringing the total to 309, including BNY’s Belgian unit for custody and transfer services. EV Battery Push: The European Commission offered interest-free loans totalling €1.5B to scale EV battery production, with projects needing at least 10 gigawatts annual capacity. Local Tech Industry: Liechtenstein’s Neutrik Americas leadership update highlights the pro-audio firm’s continued expansion across the U.S., Canada and Latin America.